Stay updated with breaking news from Mortality Weekly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After updated guidelines lowered the threshold for hypertension in 2017, prevalence remained stable through 2021, and the use of antihypertensive medications rose by 3%.
Nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
Researchers found that 8% of the 699 infants hospitalized with acute respiratory illness received nirsevimab at least 7 days before onset of symptoms.
More than half of all estimated ED visits for melatonin ingestion in under 5s involved children aged 3 to 5 years.
Single dose of nirsevimab 90% effective against RSV-associated hospitalization among infants.